Loading
A phase 1/2 trial of Test product: HYP-2090PTSA in advanced solid tumours, run by Sichuan Huiyu Pharmaceutical Co., Ltd, now recruiting.
Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation is a phase 1/2 interventional study registered as NCT06243354 by Sichuan Huiyu Pharmaceutical Co., Ltd, with 257 participants planned, started 2024-02-04 and due to reach its primary completion in 2026-12. Interventions recorded: Test product: HYP-2090PTSA.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sichuan Huiyu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Huiyu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Huiyu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Sichuan Huiyu Pharmaceutical, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares KRAS, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/